Efficacy of Cefoperazone-Sulbactam as Empirical Monotherapy Therapy for Febrile Neutropenia in Children with Solid Tumors and Lymphomas
Open Access
- 27 November 2023
- journal article
- research article
- Published by Ankara Bilkent City Hospital in Turkish Journal of Pediatric Disease
- Vol. 17 (6) , 455-460
Abstract
Objective: Monotherapy with a beta lactam or a cephalosporin has become the standard of care for the treatment of febrile neutropenia (FEN). We aimed to evaluate the efficacy of cefoperazone/sulbactam (CS) as empirical monotherapy for febrile neutropenia in children with solid tumors and lymphomas. Material and Methods: Children with FEN received cefaperazone-sulbactam (80 mg/kg/day, every 8 hours). Treatment responses (a) successful, complete resolution of all signs and symptoms of infection at 72 hours and after 7 days of CS treatment; (b) success with modification, change of therapy for viral, parasitic or fungal infection or addition of glycopeptides; (c) failure was defined as the emergence of a new or resistant infection, treatment-resistant bacteremia, the need to switch to carbapenems. Results: Our study included 157 patients and 350 febrile neutropenia episodes. The most common diagnoses were osteosarcoma (35%), Ewing sarcoma (30%), non-hodgkin lymphoma (13%) and rhabdomyosarcoma (9%), respectively. The origin of fever could not be determined in 223 (64%) of FEN episodes, 79 (22%) had microbiologically documented infection (MDI), and 48 (14%) had clinically documented infection (CDI). The success rate was 65% (229), the success rate with modification was 9% (31) and the failure rate was 26% (90). SC monotherapy was successful in 33% of attacks with MDI and in 60% of attacks with CDI. However, SC monotherapy was successful in 82% of febrile episodes of unknown origin. Conclusion: Cefoperazone/sulbactam is effective and safe in febrile neutropenic children with solid tumors and lymphomas for monotherapy.Keywords
This publication has 20 references indexed in Scilit:
- Comparison of antipseudomonal β-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysisClinical Microbiology and Infection, 2017
- The Dose-Dependent Efficacy of Cefepime in the Empiric Management of Febrile Neutropenia: A Systematic Review and Meta-AnalysisOpen Forum Infectious Diseases, 2017
- Strategies for Empiric Management of Pediatric Fever and Neutropenia in Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: A Systematic Review of Randomized TrialsJournal of Clinical Oncology, 2016
- Microorganisms isolated from cultures and infection focus and antibiotic treatments in febrile neutropenic children from Şanlıurfa, turkeyThe Turkish Journal of Pediatrics, 2016
- A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infectionsAnnals of Clinical Microbiology and Antimicrobials, 2013
- Randomized Comparison of Piperacillin–Tazobactam Plus Amikacin Versus Cefoperazone-Sulbactam Plus Amikacin for Management of Febrile Neutropenia in Children with Lymphoma and Solid TumorsPediatric Hematology and Oncology, 2013
- Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropeniaPediatric Blood & Cancer, 2011
- Comparison of Sulbactam-Cefoperazone with Carbapenems as Empirical Monotherapy for Febrile Neutropenic Children with Lymphoma and Solid TumorsPediatric Hematology and Oncology, 2011
- Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: A randomized and open‐label studyPediatric Blood & Cancer, 2009